Irritable Bowel Syndrome - Pipeline Review, H1 2018

  • ID: 4531946
  • Drug Pipelines
  • 120 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4D Pharma PLC
  • Ardelyx Inc
  • Dong-A ST Co Ltd
  • Enterome Bioscience SA
  • ImmuneBiotech AB
  • Napo Pharmaceuticals Inc
  • MORE
Irritable Bowel Syndrome - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2018, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite and constipation. These symptoms can be triggered by food, stress and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant and antibiotics medications.

Report Highlights:

This latest pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 6, 1, 8 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4D Pharma PLC
  • Ardelyx Inc
  • Dong-A ST Co Ltd
  • Enterome Bioscience SA
  • ImmuneBiotech AB
  • Napo Pharmaceuticals Inc
  • MORE
Introduction

Report Coverage

Irritable Bowel Syndrome - Overview

Irritable Bowel Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Irritable Bowel Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Irritable Bowel Syndrome - Companies Involved in Therapeutics Development

4D Pharma PLC

Allergan Plc

Ardelyx Inc

ConSynance Therapeutics Inc

Cosmo Pharmaceuticals NV

Dong-A ST Co Ltd

Eisai Co Ltd

Enterome Bioscience SA

GlaxoSmithKline Plc

ImmuneBiotech AB

Ironwood Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Metacrine Inc

Napo Pharmaceuticals Inc

RaQualia Pharma Inc

RedHill Biopharma Ltd

SK Biopharmaceuticals Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Synthetic Biologics Inc

Vitality Biopharma Inc

Irritable Bowel Syndrome - Drug Profiles

BC-1261 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bedoradrine sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Blautix - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Canchew Plus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CIN-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crofelemer DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSTI-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DA-6886 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DSP-6952 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-2508 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EB-410 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EB-420 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3179106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IB-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

linaclotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

linaclotide DR2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lovastatin MR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-4006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OP-687 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PR-38 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RDX-023 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relenopride hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rifamycin CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00310941 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TPH1 for Gastrointestinal, Metabolic Disorder and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solabegron - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tenapanor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Irritable Bowel Syndrome - Dormant Projects

Irritable Bowel Syndrome - Discontinued Products

Irritable Bowel Syndrome - Product Development Milestones

Featured News & Press Releases

Apr 25, 2018: FDA Grants Fast Track Designation for OrphoMed's ORP-101 for Treatment of IBS-D

Apr 03, 2018: AXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew Product Throughout South Korea

Mar 26, 2018: RedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA for IBS-D

Jan 17, 2018: Outpost Medicine Announces Acceptance of Two Investigational New Drug Applications for OP-687 by U.S. FDA

Jan 16, 2018: Sun Pharma Announces Settlement of Patent Litigation for Generic Linzess in US

Jan 16, 2018: RedHill Biopharma Announces Final Results from Phase II Study with BEKINDA for IBS-D

Jan 04, 2018: OrphoMed Appoints Gastroenterology Expert and Industry Veteran Mark Sostek, M.D. as Chief Medical Officer

Jan 03, 2018: Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C

Dec 12, 2017: Cosmo Pharmaceuticals Announces First Patient Randomized In Its Proof Of Concept Phase II Clinical Trial Of Rifamycin SV In IBS-D

Oct 19, 2017: Jaguar Health Subsidiary Napo Pharmaceuticals Establishes Scientific Advisory Boards for Planned Follow-on Indications for Mytesi, Napo’s FDA-approved Human Prescription Drug

Oct 16, 2017: Allergan to Present New Data on Gastrointestinal Drug Candidate Linaclotide at the World Congress of Gastroenterology at ACG 2017

Oct 16, 2017: Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling

Oct 11, 2017: Ardelyxs Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018

Oct 03, 2017: RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA in Patients with IBS-D

Sep 28, 2017: RedHill Biopharma to Announce Top-Line Results from BEKINDA 12 mg Phase II Study for IBS-D on October 3rd, 2017

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Irritable Bowel Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Irritable Bowel Syndrome - Pipeline by 4D Pharma PLC, H1 2018

Irritable Bowel Syndrome - Pipeline by Allergan Plc, H1 2018

Irritable Bowel Syndrome - Pipeline by Ardelyx Inc, H1 2018

Irritable Bowel Syndrome - Pipeline by ConSynance Therapeutics Inc, H1 2018

Irritable Bowel Syndrome - Pipeline by Cosmo Pharmaceuticals NV, H1 2018

Irritable Bowel Syndrome - Pipeline by Dong-A ST Co Ltd, H1 2018

Irritable Bowel Syndrome - Pipeline by Eisai Co Ltd, H1 2018

Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H1 2018

Irritable Bowel Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2018

Irritable Bowel Syndrome - Pipeline by ImmuneBiotech AB, H1 2018

Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals Inc, H1 2018

Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018

Irritable Bowel Syndrome - Pipeline by Metacrine Inc, H1 2018

Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H1 2018

Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc, H1 2018

Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd, H1 2018

Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2018

Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018

Irritable Bowel Syndrome - Pipeline by Synthetic Biologics Inc, H1 2018

Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H1 2018

Irritable Bowel Syndrome - Dormant Projects, H1 2018

Irritable Bowel Syndrome - Dormant Projects, H1 2018 (Contd..1), H1 2018

Irritable Bowel Syndrome - Dormant Projects, H1 2018 (Contd..2), H1 2018

Irritable Bowel Syndrome - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Irritable Bowel Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4D Pharma PLC
  • Allergan Plc
  • Ardelyx Inc
  • ConSynance Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dong-A ST Co Ltd
  • Eisai Co Ltd
  • Enterome Bioscience SA
  • GlaxoSmithKline Plc
  • ImmuneBiotech AB
  • Ironwood Pharmaceuticals Inc
  • Kissei Pharmaceutical Co Ltd
  • Metacrine Inc
  • Napo Pharmaceuticals Inc
  • RaQualia Pharma Inc
  • RedHill Biopharma Ltd
  • SK Biopharmaceuticals Co Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Synthetic Biologics Inc
  • Vitality Biopharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll